'Thursday's child has far to go'-interpreting subgroups and the STAMPEDE trial

Ann Oncol. 2017 Oct 1;28(10):2327-2330. doi: 10.1093/annonc/mdx410.

Authors

M R Spears¹, N D James², M R Sydes³

Affiliations

¹ MRC Clinical Trials Unit at UCL, Institute of Clinical Trials and Methodology, University College London, London.
² Institute of Cancer and Genomic Sciences, University of Birmingham, Birmingham, UK.
³ MRC Clinical Trials Unit at UCL, Institute of Clinical Trials and Methodology, University College London, London. Electronic address: [email protected].

No abstract available

Publication types

Editorial
Multicenter Study
Randomized Controlled Trial
Research Support, Non-U.S. Gov't

MeSH terms

Androstenes / administration & dosage
Antineoplastic Agents / administration & dosage
Data Interpretation, Statistical
Docetaxel
Humans
Male
Prostatic Neoplasms / drug therapy*
Randomized Controlled Trials as Topic / methods*
Taxoids / administration & dosage

Substances

Androstenes
Antineoplastic Agents
Taxoids
Docetaxel
abiraterone

Grants and funding